XCE Tirzepatide Manufacturer | Dual GIP/GLP-1 Receptor Agonist for Research

XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under investigation for type 2 diabetes treatment. This peptide compound demonstrates superior efficacy in glucose control and weight management compared to single-receptor agonists.

The XCE Tirzepatide formulation shows particular promise due to its balanced receptor affinity profile, with greater binding to GIP receptors than GLP-1 receptors. This unique characteristic contributes to its enhanced hyperglycemia reduction capabilities. Research indicates that XCE Tirzepatide effectively mimics natural GIP activity at the GIP receptor while maintaining significant GLP-1 receptor engagement.

Our XCE Tirzepatide is supplied as a white powder with exceptional purity levels, making it ideal for research applications. The compound is carefully synthesized and purified to meet rigorous pharmaceutical standards, ensuring reliable performance in laboratory settings.

Note: This product is intended for research purposes only and not for human consumption.